Production Linked Incentive (PLI) schemes have been introduced across 14 sectors to realise India’s vision of becoming a global manufacturing hub. The schemes aim to enhance scale and competitiveness in selected sectors and provide a strong impetus to domestic manufacturing. This report presents a sector-wise assessment of the impact of PLI schemes, which have been instrumental in reshaping India’s manufacturing trajectory.
The assessment indicates that the PLI Scheme is beginning to generate meaningful additionality across several sectors, although the extent and nature of the impact vary considerably depending on the maturity of the sector, the technological complexity of the products and the gestation period of investments. Sectors such as large-scale electronics manufacturing, Pharmaceuticals Drugs, food processing, drones, medical devices and white goods show relatively strong evidence of progress across multiple parameters. Other sectors, including automobiles and auto components, telecom and Speciality steel, demonstrate encouraging progress, particularly in investment and production, but require further strengthening in areas such as employment, exports and domestic value addition. In relatively newer or more capital-intensive sectors such as ACC batteries and advanced electronic components, outcomes remain at an early stage, with substantial investments still in the capacity-creation and commissioning phase. The sectorwise findings therefore need to be interpreted in the context of the differing implementation timelines and investment-to-production cycles of individual schemes.
Large Scale Electronics Manufacturing (LSEM) with an outlay of ₹34,193 crore has emerged as one of the strongest performers, particularly in mobile manufacturing, with significant growth in production, sales, exports and employment across both domestic and global firms. The scheme has successfully expanded production, attracted investment, and generated employment, while also laying the foundation for the recently launched Electronics Component Manufacturing Scheme (ECMS) with an outlay of ₹40,000 crore. Overall, the LSEM scheme shows strong progress, particularly in mobile manufacturing. The Pharma Bulk Drugs scheme with an outlay of ₹6,940 Crore presents a more differentiated picture across its four target segments. Target Segment IV – Other Chemical Synthesis Based KSMs/Drug Intermediates/APIs has been the strongest and most consistent performer, while Target Segment I has recorded a relatively late but sharp production scale-up and Target Segment II has shown gradual growth from a low base. In contrast, Target Segment III – Key Chemical Synthesis Based KSMs/Drug Intermediates has experienced vulnerability across indicators. A sharp increase in investment during FY 2024–25 nevertheless indicates renewed industry confidence. Overall, the scheme has generated additional growth, but with significant variation across segments.
The Advanced Chemistry Cell (ACC) Battery scheme, with an outlay of ₹18,100 crore, is intended to establish 50 GWh of domestic ACC capacity and 5 GWh of niche battery capacity. Progress, however, remains at an early stage, with only 1.4 GWh of capacity developed so far and no commercial production or incentive disbursement yet. Most participating firms remain engaged in infrastructure and capacity creation.
Read: https://www.niti.gov.in/sites/default/files/2026-11/Impact-Assessment-of-PLI-Schemes.pdf



.png)


